As back­lash mounts in the wake of a dis­as­trous PhI­II flop, Ei­sai goes deep­er with 2 new hires

While Bio­gen buck­les un­der in­tense crit­i­cism for the Phase III fail­ure of ad­u­canum­ab for Alzheimer’s — trig­ger­ing a re­view of what it should fo­cus on next — its long­time neu­ro­sciences part­ner Ei­sai con­tin­ues to build its in­vest­ment in their con­tro­ver­sial R&D work.

The bio­phar­ma play­er has re­cruit­ed a pair of se­nior ex­ecs to join the Alzheimer’s team at Ei­sai, which stirred a con­sid­er­able fuss with a ham-hand­ed de­ci­sion to start a Phase III tri­al for BAN2401 right af­ter Bio­gen was forced to try and ex­plain the ad­u­canum­ab flop — af­ter build­ing their late-stage pipeline around that project.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.